PE20110291A1 - Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico - Google Patents
Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepilepticoInfo
- Publication number
- PE20110291A1 PE20110291A1 PE2011000206A PE2011000206A PE20110291A1 PE 20110291 A1 PE20110291 A1 PE 20110291A1 PE 2011000206 A PE2011000206 A PE 2011000206A PE 2011000206 A PE2011000206 A PE 2011000206A PE 20110291 A1 PE20110291 A1 PE 20110291A1
- Authority
- PE
- Peru
- Prior art keywords
- phenol
- propyl
- ethyl
- methyl
- antiepyleptic
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 abstract 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- KWTWDQCKEHXFFR-RISCZKNCSA-N 3-[(2s,3s)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@@H](C)[C@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-RISCZKNCSA-N 0.000 abstract 1
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 abstract 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000623 carbamazepine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229960001848 lamotrigine Drugs 0.000 abstract 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 abstract 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 abstract 1
- 229960003404 mexiletine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 abstract 1
- 229960004394 topiramate Drugs 0.000 abstract 1
- 229960000604 valproic acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08015625 | 2008-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110291A1 true PE20110291A1 (es) | 2011-06-04 |
Family
ID=40345058
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000206A PE20110291A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2014001116A PE20142371A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2014001115A PE20142357A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2018003303A PE20190914A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2014001117A PE20142372A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001116A PE20142371A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2014001115A PE20142357A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2018003303A PE20190914A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
| PE2014001117A PE20142372A1 (es) | 2008-09-05 | 2009-09-04 | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20100063148A1 (enExample) |
| EP (2) | EP2331210B1 (enExample) |
| JP (4) | JP5731387B2 (enExample) |
| KR (3) | KR101730924B1 (enExample) |
| CN (2) | CN105520924B (enExample) |
| AR (2) | AR073361A1 (enExample) |
| AU (3) | AU2009289776A1 (enExample) |
| BR (1) | BRPI0920521A2 (enExample) |
| CA (1) | CA2735857C (enExample) |
| CL (1) | CL2011000317A1 (enExample) |
| CO (1) | CO6382142A2 (enExample) |
| CY (2) | CY1115751T1 (enExample) |
| DK (2) | DK2331210T3 (enExample) |
| EC (1) | ECSP11010869A (enExample) |
| ES (2) | ES2513394T3 (enExample) |
| HR (2) | HRP20140663T1 (enExample) |
| HU (1) | HUE043278T2 (enExample) |
| IL (3) | IL211135A (enExample) |
| LT (1) | LT2735338T (enExample) |
| MX (1) | MX2011002339A (enExample) |
| PE (5) | PE20110291A1 (enExample) |
| PL (2) | PL2331210T3 (enExample) |
| PT (2) | PT2331210E (enExample) |
| RU (2) | RU2571501C2 (enExample) |
| SI (2) | SI2331210T1 (enExample) |
| TR (1) | TR201904388T4 (enExample) |
| WO (1) | WO2010025931A2 (enExample) |
| ZA (1) | ZA201101449B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| PL2462990T3 (pl) | 2006-06-15 | 2014-05-30 | Ucb Pharma Gmbh | Kompozycja farmaceutyczna obejmująca lakozamid i lewetyracetam o synergistycznym działaniu przeciwdrgawkowym |
| US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| LT2735338T (lt) * | 2008-09-05 | 2019-04-10 | Grünenthal GmbH | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys |
| FR2943246B1 (fr) * | 2009-03-19 | 2011-07-29 | Biocodex | Compose pour son utilisation dans le traitement des neuropathies peripheriques |
| AU2011267474B2 (en) * | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| EP2590636A1 (en) | 2010-07-06 | 2013-05-15 | Grünenthal GmbH | Novel gastro- retentive dosage forms comprising a gaba analog and an opioid |
| JP5786714B2 (ja) | 2010-07-30 | 2015-09-30 | 東レ株式会社 | 神経障害性疼痛の治療剤又は予防剤 |
| EA028149B1 (ru) * | 2011-03-04 | 2017-10-31 | Грюненталь Гмбх | Парентеральное введение тапентадола |
| ES2712072T3 (es) * | 2011-07-20 | 2019-05-09 | Torrent Pharmaceuticals Ltd | Composición farmacéutica de tapentadol |
| PT2736501T (pt) * | 2011-07-29 | 2018-03-26 | Gruenenthal Gmbh | Administração intratecal ou epidural de 3-[(1s,2s)-3-(dimetilamino)-1-etil-2-metilpropil]fenol |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9855286B2 (en) * | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| US9629818B2 (en) * | 2012-11-01 | 2017-04-25 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of tapentadol for parenteral administration |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CN103655523A (zh) * | 2013-12-24 | 2014-03-26 | 南京艾德凯腾生物医药有限责任公司 | 他喷他多组合物 |
| RU2020128323A (ru) | 2015-12-22 | 2020-10-06 | Зодженикс Интернэшнл Лимитед | Фенфлураминовые композиции и способы их получения |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| KR20250040753A (ko) * | 2016-08-24 | 2025-03-24 | 조게닉스 인터내셔널 리미티드 | 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법 |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3883555A1 (en) | 2018-11-19 | 2021-09-29 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| JP4977297B2 (ja) * | 1999-08-20 | 2012-07-18 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | トラマドール物質及び抗痙攣薬を含んで成る組成物 |
| AU2003210486B2 (en) * | 2002-01-16 | 2007-06-28 | Endo Pharmaceuticals Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| IL162932A0 (en) * | 2002-02-22 | 2005-11-20 | Warner Lambert Co | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
| WO2007005716A2 (en) | 2005-06-30 | 2007-01-11 | Cinergen, Llc | Methods of treatment and compositions for use thereof |
| WO2007087452A2 (en) * | 2006-01-27 | 2007-08-02 | Theraquest Biosciences, Llc | Abuse resistant and extended release formulations and method of use thereof |
| MX2008013828A (es) * | 2006-04-28 | 2008-11-10 | Gruenenthal Gmbh | Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid. |
| WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| WO2009067703A2 (en) * | 2007-11-23 | 2009-05-28 | Nectid, Inc. | Tapentadol compositions |
| JP5291123B2 (ja) * | 2008-01-25 | 2013-09-18 | ゼノポート，インコーポレイティド | （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用 |
| LT2735338T (lt) * | 2008-09-05 | 2019-04-10 | Grünenthal GmbH | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys |
-
2009
- 2009-09-04 LT LTEP14000597.6T patent/LT2735338T/lt unknown
- 2009-09-04 EP EP09778335.1A patent/EP2331210B1/en active Active
- 2009-09-04 DK DK09778335.1T patent/DK2331210T3/da active
- 2009-09-04 SI SI200931014T patent/SI2331210T1/sl unknown
- 2009-09-04 KR KR1020167018592A patent/KR101730924B1/ko not_active Expired - Fee Related
- 2009-09-04 PL PL09778335T patent/PL2331210T3/pl unknown
- 2009-09-04 RU RU2011112444/15A patent/RU2571501C2/ru active
- 2009-09-04 CN CN201510736012.5A patent/CN105520924B/zh not_active Expired - Fee Related
- 2009-09-04 JP JP2011525465A patent/JP5731387B2/ja active Active
- 2009-09-04 DK DK14000597.6T patent/DK2735338T3/en active
- 2009-09-04 SI SI200931945T patent/SI2735338T1/sl unknown
- 2009-09-04 PE PE2011000206A patent/PE20110291A1/es active IP Right Grant
- 2009-09-04 BR BRPI0920521A patent/BRPI0920521A2/pt not_active Application Discontinuation
- 2009-09-04 KR KR1020117005044A patent/KR101641519B1/ko not_active Expired - Fee Related
- 2009-09-04 ES ES09778335.1T patent/ES2513394T3/es active Active
- 2009-09-04 PE PE2014001116A patent/PE20142371A1/es active IP Right Grant
- 2009-09-04 HU HUE14000597A patent/HUE043278T2/hu unknown
- 2009-09-04 US US12/554,235 patent/US20100063148A1/en not_active Abandoned
- 2009-09-04 KR KR1020177010825A patent/KR101851120B1/ko not_active Expired - Fee Related
- 2009-09-04 PE PE2014001115A patent/PE20142357A1/es active IP Right Grant
- 2009-09-04 CA CA2735857A patent/CA2735857C/en not_active Expired - Fee Related
- 2009-09-04 RU RU2014138166A patent/RU2674150C1/ru active
- 2009-09-04 AR ARP090103405A patent/AR073361A1/es not_active Application Discontinuation
- 2009-09-04 PE PE2018003303A patent/PE20190914A1/es unknown
- 2009-09-04 PL PL14000597T patent/PL2735338T3/pl unknown
- 2009-09-04 EP EP14000597.6A patent/EP2735338B1/en not_active Not-in-force
- 2009-09-04 AU AU2009289776A patent/AU2009289776A1/en not_active Abandoned
- 2009-09-04 MX MX2011002339A patent/MX2011002339A/es active IP Right Grant
- 2009-09-04 PE PE2014001117A patent/PE20142372A1/es active IP Right Grant
- 2009-09-04 WO PCT/EP2009/006424 patent/WO2010025931A2/en not_active Ceased
- 2009-09-04 PT PT97783351T patent/PT2331210E/pt unknown
- 2009-09-04 HR HRP20140663AT patent/HRP20140663T1/hr unknown
- 2009-09-04 PT PT14000597T patent/PT2735338T/pt unknown
- 2009-09-04 CN CN200980135117.8A patent/CN102159284B/zh not_active Expired - Fee Related
- 2009-09-04 TR TR2019/04388T patent/TR201904388T4/tr unknown
- 2009-09-04 ES ES14000597T patent/ES2719900T3/es active Active
-
2011
- 2011-02-09 IL IL211135A patent/IL211135A/en active IP Right Grant
- 2011-02-14 CL CL2011000317A patent/CL2011000317A1/es unknown
- 2011-02-16 CO CO11018461A patent/CO6382142A2/es active IP Right Grant
- 2011-02-23 ZA ZA2011/01449A patent/ZA201101449B/en unknown
- 2011-03-04 EC EC2011010869A patent/ECSP11010869A/es unknown
-
2014
- 2014-09-16 CY CY20141100748T patent/CY1115751T1/el unknown
- 2014-12-12 JP JP2014251851A patent/JP2015096530A/ja active Pending
-
2015
- 2015-02-24 IL IL237392A patent/IL237392B/en active IP Right Grant
- 2015-02-24 IL IL237391A patent/IL237391A/en active IP Right Grant
-
2016
- 2016-05-11 AU AU2016203053A patent/AU2016203053B2/en not_active Ceased
- 2016-12-12 JP JP2016240032A patent/JP2017071636A/ja active Pending
-
2018
- 2018-04-26 AU AU2018202879A patent/AU2018202879B2/en not_active Ceased
-
2019
- 2019-03-13 HR HRP20190500TT patent/HRP20190500T1/hr unknown
- 2019-03-27 CY CY20191100357T patent/CY1121492T1/el unknown
- 2019-04-02 JP JP2019070282A patent/JP2019131578A/ja active Pending
- 2019-07-19 AR ARP190102034A patent/AR117613A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110291A1 (es) | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| PE20090605A1 (es) | Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma | |
| GT201200020A (es) | Composición de insulina de acción prolongada | |
| PE20130243A1 (es) | Combinacion farmaceutica | |
| CL2011001027A1 (es) | Compuestos derivados de 1-(benzo[d][1,3]dioxol-6-il]-n(1h-indol-5-il)ciclopropano carboxamida; moduladores abc; composicion farmaceutica que los comprende; metodo in vitro de incremento de transportadores abc; kit farmaceutico; y su uso en el tratamiento de fibrosis quisticas, problemas metabolicos, del snc, entre otros. | |
| PE20120858A1 (es) | Composiciones solidas que comprenden acido 5-aminolevulinico | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| PE20120713A1 (es) | Composiciones sublinguales de dexmedetomidina y metodos para su uso | |
| CL2011002989A1 (es) | Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros. | |
| CL2008003261A1 (es) | Composición farmaceutica en forma de suspension que comprende carisbamato, hipromelosa y agua; proceso para prepararla y su uso para tratar enfermedades tales como epilepsia, dolor neuropatico, temblor y esquizofrenia, entre otras. | |
| CO6460715A2 (es) | Sistema para el cuidado bucal, dispositivo y método | |
| MX2012010048A (es) | Composicion para esterilizacion libre de molibdato que contiene acido peracetico. | |
| AR098576A1 (es) | Producto farmacéutico | |
| PE20121709A1 (es) | Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica | |
| PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
| PE20091715A1 (es) | Variantes de igf-i pegiladas y composiciones que las contienen | |
| MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
| MX2015008528A (es) | Formulaciones para conservacion de organos y tejidos con estabilidad y vida util aumentadas. | |
| ES2673406T3 (es) | Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes | |
| CL2009001366A1 (es) | Compuestos derivados de heterociclil-sulfonamidas con un grupo de cabeza de heterociclo y oxadiazolona; composicion farmaceutica y su proceso de preparacion; y su uso para el tratamiento y/o prevencion de trastornos del metabolismo de acidos grasos y de la glucosa, tal como diabetes mellitus, resistencia a la insulina, dislipidemias, entre otras. | |
| CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
| PE20110305A1 (es) | Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid | |
| BR112014014207A2 (pt) | análogos de magnolol solubilizados | |
| ECSP099734A (es) | Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| AE | Restoration of lapsed or forfeited application | ||
| FG | Grant, registration |